 |
|
|
DRUG-DRUG INTERACTIONS: SCIENTIFIC AND REGULATORY PERSPECTIVES, 43
| |
| | |
|
|
To order this title, and for more information, click here
J. August, John Hopkins University; Department of Pharmacology, Baltimore, Maryland, U.S.A.
Albert Li, In Vitro Technologies, Inc., and University of Maryland Technology Center, Baltimore, Maryland, U.S.A.
Ferid Murad, University of Texas Medical School, Houston, U.S.A.
M. Anders, University of Rochester; Department of Pharmacology, New York, U.S.A.
Joseph Coyle, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, U.S.A.
Reviews
--NATURE, Praise for the Series
"Recommended not only to pharmacologists but also to all those in related disciplines."
--H.E. Kaufmann in CHEMOTHERAPY
"The works do represent an extensive compilation of recent data by outstanding researchers in this area. They are generally scientifically
excellent, the bibliographies are good, and the individual reports are clear, concise, and extremely well illustrated."
--JOURNAL OF PHARMACEUTICAL SCIENCES
"Superb reading material."
--Rajendar Mehta, PhD, University of Illinois at Chicago College of Medicine for DOODY'S PUBLISHING
"This book represents a comprehensive review of drug-drug interaction and is unique since the contributors are from all facets of the
workplace, including academic institutes, government, and industry... The most attractive feature of the book is its well-focused subject
area with the emphasis on the importance of P-450 enzymes in drug interactions and how government regulatory agencies evaluate them...
It is unique since it presents the regulatory aspects of drug evaluations as an integral part of the science of drug-drug interactions."
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company